Peptidotriazolamers Inhibit Aβ(1–42) Oligomerization and Cross a Blood‐Brain‐Barrier Model
作者:Nicolo Tonali、Loreen Hericks、David C. Schröder、Oliver Kracker、Radosław Krzemieniecki、Julia Kaffy、Vadim Le Joncour、Pirjo Laakkonen、Antoine Marion、Sandrine Ongeri、Veronica I. Dodero、Norbert Sewald
DOI:10.1002/cplu.202000814
日期:2021.6
G39VVIA42 in Aβ(1–42). We found that peptidotriazolamers act as modulators of the Aβ(1–42) oligomerization. Some peptidotriazolamers are able to interfere with the formation of toxic early Aβ oligomers, depending on the position of the triazoles, which is also supported by computational studies. Preliminary in vitro results demonstrate that a highly active peptidotriazolamer is also able to cross the blood-brain-barrier
在肽三唑仑中,每隔一个肽键被 1 H -1,2,3-三唑取代。这种折叠体有望弥合小分子药物和基于蛋白质的药物之间的分子量差距。淀粉样蛋白 β (Aβ) 聚集体在阿尔茨海默病中起重要作用。我们研究了 1,4-二取代的 1 H -1,2,3-三唑取代酰胺键对聚集“热点”K 16 LVFF 20和 G 39 VVIA 42抑制活性的影响在 Aβ(1-42) 中。我们发现肽三唑仑可作为 Aβ(1-42) 寡聚化的调节剂。一些肽三唑仑能够干扰有毒的早期 Aβ 低聚物的形成,这取决于三唑的位置,这也得到了计算研究的支持。初步体外结果表明,高活性肽三唑仑也能够穿过血脑屏障。